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Abstract
Background: Evidence-informed clinical practice guidelines (CPGs) are useful tools to inform transparent healthcare
decision-making. Consideration of health economic evidence (HEE) during CPG development in a structured
manner remains a challenge globally and locally. This study explored the views, current practice, training needs and
challenges faced by CPG developers in the production and use of HEE for CPGs in South Africa.
Methods: This mixed-methods study comprised an online survey and a focus group discussion. The survey was
piloted and subsequently sent to CPG role players - evidence reviewers, CPG panellists, academics involved with
training in relevant disciplines like health economics and public health, implementers and funders. The focus group
participants hold strategic roles in CPG development and health economic activities nationally. The survey
evaluated mean values, measures of variability, and percentages for Likert scales, while narrative components were
thematically analysed. Focus group data were manually coded, thematically analysed and verified.
Results: The survey (n = 55 respondents to 245 surveys distributed) and one focus group (n = 5 participants from
10 people invited) occurred between October 2018 and February 2019. We found the most consistent reason why
HEE should inform CPG decisions was ‘making more efficient use of limited financial resources’. This was explained
by numerous context and methodological barriers. Focus groups participants noted that consideration of complex
HEE are not achievable without bolstering skills in applying evidence-based medicine principles. Further concerns
include lack of clarity of standard methods; inequitable and opaque topic selection across private and public
sectors; inadequate skills of CPG panel members to use HEE; and the ability of health economists to communicate
results in accessible ways. Overall, in the absence of clarity about process and methods, politics and interests may
drive CPG decisions about which interventions to implement.
Conclusions: HEE should ideally be considered in CPG decisions in South Africa. However, this will remain
hampered until the CPG community agree on methods and processes for using HEE in CPGs. Focused investment
by national government to address the challenges identified by the study is imperative for a better return on
investment as National Health Insurance moves forward.
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Background
Healthcare funders, commissioners and operational
managers in the public and private sectors are expected
to select, fund and implement health interventions and
services that represent the best use of available health re-
sources in their local context. Clinical practice guidelines
(CPGs) that are informed by systematic reviews of the
available clinical and economic evidence are useful tools
to aid transparent healthcare decision-making [1, 2].
Health economic evidence (HEE) can be produced using
a variety of methodological approaches such as budget
impact assessment, cost-effectiveness analysis or cost-
utility analysis to name a few. The type of HEE produced
and the degree to which it is incorporated in CPG devel-
opment depend on the intervention type, data availabil-
ity, and the availability of technical skills of those
synthesising the evidence and those who need to use the
evidence. Ultimately, the inclusion of the best available
effectiveness and economic evidence should enable the
decision-maker to make a more informed decision.
In South Africa, the Essential Drugs Programme at the
National Department of Health supports the creation
and maintenance of the national Essential Medicines List
(EML) by coordinating the production of systematic re-
views and costing analyses, including Health Technology
Assessments (HTAs), and convening ministerial-
appointed committees to appraise evidence and make
decisions regarding the selection/deselection of tech-
nologies to the EML. Essential Medicines List decisions
feed into the production of the Standard Treatment
Guidelines, which are the implementation mechanisms
for the EML and provide guidance to health care profes-
sionals on the rational use of the essential medicines at a
particular level of care. Currently the scope of the HTAs
and analyses that inform EML decisions vary depending
on the review question, with economic analyses only
conducted and reported for selected topics. The clinical
and economic evidence informing private sector formu-
laries, and by extension treatment protocols, are also
variable, with HTA processes and evidence requirements
differing significantly between organisations.
Recent research on CPG development and practices by
the South African Guidelines Excellence (SAGE) project
highlighted the need to improve CPG quality, training,
development and reporting methodology, and to in-
crease the involvement of end-users in the CPG develop-
ment process [3]. Internationally, published literature
and governmental publications indicate the need for
more rigorous methods and processes to ensure CPG
recommendations are informed by the best available evi-
dence, including cost-effectiveness, resource use and
equity [4–6]. It also shows that the utilisation of HEE in
the production of CPGs by health authorities is already
ongoing to varying degrees [4, 7–9]. For example, HEE
is taken into account when making medicine reimburse-
ment decisions globally, including in South Africa [10],
and in some cases these decisions are reflected in related
CPGs. However, the manner in which economic evi-
dence is used in CPG development is less explicit [7],
less agreed upon or understood [11], and still very much
an evolving discipline [12]. This might partly be due to
the fact that the type of HEE and the manner in which it
can be used in CPG development is dependent on coun-
try specific health systems, benefit packages, budgets,
and value preferences [4, 7, 11, 12]. Therefore, even
though there are basic underlying principles of how HEE
can be used to inform CPG recommendations, the de-
tailed processes and methods used in a specific country
or health system should be based on its particular needs,
constraints and value preferences.
The South African healthcare sector operates in a con-
strained resource environment with a complex, two-tier
system. The private health insurance sector covers ap-
proximately 16% of the population and the remaining
population is covered by the public sector with funding
from both national and provincial sources (mostly pro-
vincial). This situation leads to substantial differences in
healthcare costs, demands, financing mechanisms, bene-
fit packages and incentives [13, 14]. The private health-
care market was recently investigated by the
Competition Commission (Health Market Inquiry) with
findings and recommendations published in 2019 [13].
The Inquiry found that the private health care market is
characterised by “high and rising costs of healthcare and
medical scheme cover, and significant overutilization
without stakeholders having been able to demonstrate
associated improvements in health outcomes” [13].
Among the issues identified is a lack of transparent,
standardised methods to measure and compare the cost-
effectiveness of healthcare interventions [13].
Through a financing mechanism called National
Health Insurance (NHI), South Africa has introduced
and is planning a series of reforms over the next few de-
cades to introduce Universal Health Coverage (UHC)
[15]. The intention is to improve the quality of care in
the public sector and to better co-ordinate health
provision across the public and private sectors. The
health benefits that will be provided will require devel-
opment of CPGs based on the best available clinical and
cost-effectiveness evidence [15]. However, CPG develop-
ment is currently fragmented, with no formal co-
ordination between the public and private sector in
terms of topic selection, methodological approaches,
reporting standards or implementation strategies [16].
Cochrane South Africa and the Centre for Evidence
Based Health Care (both SAGE partners), and the South
African Medical Research Council Centre for Health
Economics and Decision Science, PRICELESS SA,
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initiated this study to understand if and how HEE could
be used to inform CPG development in South Africa. As
a starting point, the research team considered it essential
to identify role players and better understand the atti-
tudes, technical experience and needs, and challenges
faced by CPG developers in relation to the production
and use of HEE in CPGs.
Methods
The aim of the study was to assess the views, current
practice, training needs and challenges faced by CPG
stakeholders in relation to production and use of HEE in
CPG development. The specific objectives were to iden-
tify the views, including barriers and facilitators, by CPG
stakeholders involved in the production and use of HEE
in CPG development; determine the extent to which
HEE are currently produced for and used in CPGs; and
explore the technical capacity and training needs of CPG
stakeholders with respect to production and use of HEE.
Design of the study
This mixed-methods study consisted of an online survey
followed by a qualitative focus group discussion [17]. By
combining qualitative and quantitative methods we were
able to deepen the understanding of data through tri-
angulation of results collected from different sources
[18].
Survey: An online survey (in the form of a structured
questionnaire) aimed to collect descriptive qualitative
and quantitative data from a predefined group of re-
spondents. Respondents completed the online survey in-
dependent from a researcher and at their own
convenience during a specified time period [19].
Focus group: The focus group discussion aimed to ver-
ify survey results as well as identify areas not adequately
addressed by the survey and prioritised content for further
HEE capacity building. Focus group participants were en-
couraged to communicate with one another, exchange
ideas and comment on each other’s experiences or points
of view. This approach was useful because participants
reacted to and built on the responses of others, and it
allowed the facilitator to probe participants to elaborate
on specific issues or ask them for clarification [19].
Eligibility and sample
Survey: Targeted invitations were emailed to CPG devel-
opers (purposive sampling method). The term ‘CPG de-
velopers’ comprised all role players involved CPG
development, including producers/ synthesisers of evi-
dence; members of CPG panels; institutions that provide
training in relevant disciplines such as health economics,
biostatistics, clinical epidemiology, and public health; in-
dividuals involved in CPG implementation; and funders
of CPG development and implementation. CPG
developers were identified from a CPG mapping project
[16], SAGE CPG interest group membership, an online
search for South African stakeholders who published ar-
ticles related to health economics in the last 10 years,
and a review of institutions/departments providing ana-
lytical services or formal training in health economic evi-
dence production. In addition, survey recipients were
encouraged to share the survey with other stakeholders
in similar roles or who could provide insight to the study
area (snowball sampling method). There were no limits
on the sample size to enable this survey to capture as
broad an input as possible. The survey was sent to 245
people involved in CPG development, use or implemen-
tation in October 2018.
Focus group: Following the survey analysis, a focus
group was held in February 2019. Participants were pur-
posively selected, based on knowledge of stakeholders
that play a strategic role in CPG development and/or
HEE production and training activities. Ten stakeholders
were invited to participate in the focus group discussion
and five were available to participate on the day of the
focus group due to competing work commitments.
Description and use of study materials
Survey: No validated questionnaires addressing all the
research objectives were available. For this reason, a new
questionnaire was developed with two questions adapted
from a survey produced by the Health Intervention and
Technology Assessment Program (HITAP) in Thailand
[20]. This was included to address objective one about
preferences and challenges of CPG developers in relation
to production and use of HEE in CPG development. Add-
itional questions were formulated to address other study
objectives based on key considerations and concerns re-
garding the use of HEE in CPGs from published litera-
ture [4, 7, 12, 21] and suggestions by South African
experts in the field of health economics and CPGs. The
survey adhered to the STROBE checklist for cross-
sectional studies [22]. English was an acceptable lan-
guage for the study population. The questionnaire was
piloted with a representative sample (n = 9 respondents)
to ensure the questions were easily understandable and
addressed the study objectives. Survey questions were re-
vised based on this feedback before sending it to the sur-
vey sample population. Sixty responses (out of 245
surveys distributed) were received of which 55 partici-
pants were eligible. Participants typically spent 26 min
completing the survey and the average completion rate
was 73%. All survey respondents answered a qualifier
question to ensure they were eligible to participate (re-
spondents were asked to select or state their CPG-
related experience). The survey was administered elec-
tronically, using an online survey tool (SurveyMonkey®).
A reminder was sent one week before the survey closing
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date. Using the functionality of SurveyMonkey® tool, the
‘Anonymous Responses’ option was selected, therefore
no personally identifiable data were collected about the
survey participants. All eligible participants gave their
consent to participate and agreed that their anonymised
survey response could be used in future research reports
or publications.
Focus group: Specific questions were prepared in a
semi-structured topic guide. Questions were based on
the survey findings and gaps in this data. The focus
group was held face-to-face at the School of Public
Health at the University of Witwatersrand in Johannes-
burg, and conducted by an experienced facilitator. Key
findings from the survey were presented to the focus
group participants, after which they were encouraged to
ask questions and provide feedback, thereby verifying or
refuting the results. The focus group discussion was
digitally recorded with the permission of the partici-
pants, and the audio-recording was transcribed verbatim
and checked against the recording for accuracy.
Analysis
Survey data were analysed using quantitative and quali-
tative methods. Summary methods were used to evaluate
mean values and measures of variability, and percentages
to evaluate the Likert scales. Narrative components were
thematically analysed.
Focus group data were manually coded independently
by two researchers (MW, BMS) and a third researcher
checked the codes (TK) [19]. These were then presented
to the entire research team in an analysis meeting for
verification and agreement. A deductive approach was
used, in which the survey questions were used as the key
themes; together with an inductive approach in which
emergent themes addressing general issues relating to
the use of HEE in CPGs were captured.
Results
We report the results of a survey and the subsequent
focus group discussion. Fifty-five eligible participants
responded to 245 surveys distributed. The respondents
had a variety of CPG-related experience ranging from
evidence production (n = 32); evidence use (n = 31), with
fewer involved with training (n = 20); implementation
(n = 19) and/or funding (n = 8). Most were aged 36–50
years (44%, 24/55), followed by those over 50 (38%, 21/
55) and those aged 18–35 years (18%, 10/55). The major-
ity (93%) were from the Western Cape Province (42%,
23/55), Gauteng (42%, 23/55) and Kwa-Zulu Natal (9%,
5/55). Many respondents worked in academic or re-
search environments (45%, 25/55) and almost 80% (43/
55) held a masters (30/55) or doctorate (13/55)
qualification.
The five focus group participants were from Gauteng
Province (n = 2), Eastern Cape (n = 1) and Western Cape
(n = 2) and each had multiple roles relevant to this study,
namely: evidence producers; evidence users; funders;
training or research institutions; or implementation spe-
cialists. They represented academia, a professional asso-
ciation (private sector), and the National Department of
Health, and by discipline represented healthcare pro-
viders (medical specialist, pharmacist), public health spe-
cialists, and health economists.
Views on production and use of HEE in CPG development
Most survey respondents (48/53) considered the use of
HEE in CPGs very important (30/53) or quite important
(18/53) and selected key justifications of why HEE
should be used in CPG development (Fig. 1). ‘Making
more efficient use of limited financial resources’ was
considered the most important, followed by the consid-
eration that HEE allows a more ‘balanced view of the po-
tential costs and benefits of a CPG recommendation’.
The importance of the affordability and sustainability of
CPG recommendations were highlighted by some re-
spondents under the ‘other’ option. Focus group partici-
pants echoed these justifications with one participant
stating that ‘if the final decision-making body in this
country is not using health economic information; we’re
in a really horrible space’ [FGP_5].
Reasons that HEE is not used in CPG development
‘Limited technical capacity’ was cited as the most im-
portant barrier to the use of HEE in CPGs (42/55 re-
spondents), followed by ‘the wide uncertainty in the
results of economic evaluations due to analysis
methods and/or lack of reliable data’ (32/55 respon-
dents) (Fig. 2). Additional barriers to the use of HEE
in CPGs were provided under the ‘other’ category,
and included limited understanding of the role of
HEE (and its underlying principles); weak leadership
in raising awareness of this role; poorly managed con-
flicts of interest; limited funding and skills; and non-
transparent topic selection and scoping practices for
economic evaluations. Focus group participants
expressed concern that there is a lack of clarity about
which kinds of HEE analyses are required for particu-
lar situations. This is compounded by focus group
participants’ experience that incorporating HEE in
decision-making adds complexity to an already diffi-
cult process. Some focus group participants felt that
CPG developers already struggle with application of
evidence-based medicine principles and so adding fur-
ther requirements may be ‘pointless’ until guideline
methods are better implemented.
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Topic selection for HEE analyses
The potential resource implication of introducing an
intervention was considered the most important factor
for topic selection (46/50 respondents), followed by
high-level uncertainty about cost-effectiveness (34/50)
and the availability of robust data (31/50) (Fig. 3). Add-
itional topic selection criteria included making better
use of and adapting internationally produced evidence
when possible so that available resources can be more
efficiently used, responding to stakeholder requests, and
the wider economic and clinical impact of an interven-
tion. Focus group participants proposed that South Afri-
can CPG developers should be ‘pragmatic’ and that ‘not
everything needs to be subjected to economic evaluation.
Sometimes we will do the back of the matchbox calcula-
tions, and that is sufficient’. Full economic evaluations
may be needed for ‘very costly’ or ‘new interventions’ or
when benefit is considered ‘borderline’. Focus group par-
ticipants thought that topic selection was impacted by
the limited capacity and resources available to invest in
Fig. 1 Reasons that economic evidence should be considered in CPG development
Fig. 2 Reasons for not including economic evidence in guideline development
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conducting economic analysis, resulting in other drivers
for topic selection, as described in these quotes: ‘deci-
sions are not made on evidence, they are made on polit-
ical whim’ [FGP_2] and that many ‘ground decisions are
purely politics or personalities’ [FGP_5].
Methods-specific issues affecting use of HEE in CPGs
Most respondents (49%, 25/51) were unsure if the
methods currently used to gather, analyse and report
economic evidence could usefully inform CPG develop-
ment, while 29% (15/51) said the methods are useful and
22% (11/51) said they were not. Forty-four respondents
provided specific methodological issues they considered
a barrier to the use of HEE in CPGs such as availability
of clinical and costing data; lack of standardisation; poor
reporting of results; lack of transparency; lack of skills
and funding; and issues relating to the disparity between
private and public (state) funded care. Proposed solu-
tions included improved reporting standards; investment
in clinical and costing research; training; and the use of
standardised methodology. A thematic analysis to under-
stand methodological issues and proposed solutions was
conducted and is presented in Table 1. Focus group par-
ticipants agreed with the survey respondents regarding
differing methodologies and reporting and lack of agree-
ment on standards perceived as ‘a problem globally not
just for a particular country’ made more fraught by the
politics and the ‘contested space and … .. varied views
Fig. 3 Factors to consider in selection of topics for health economic evaluation
Table 1 Methodological barriers to health economic evidence use in CPG development
Thematic areas Sub-themes Solutions
1. Lack of agreed methods and
reporting standards
• Inconsistent methods / poor standardisation
(e.g. clinical end-points or comparators selected)
• Poor reporting of methods
• Methods not agreed by stakeholders in South Africa
• Develop methods and reporting standards
informed by broad based stakeholder
consultation
2. Lack of available data • Data from South Africa of costs:
- Costs vary by sectors (i.e. public vs. private), settings (e.g.
provinces) and levels of care (i.e. primary vs secondary)
- Poor availability of costing data
• Outcomes data to inform decisions
• Strengthen data collection systems
• Develop registries for data collection
• Investment in research
3. Lack of skills to conduct analyses
and use economic evidence
• Lack of trained health economists, statisticians,
mathematicians, team with multi-disciplinary skills
• Lack of skills for CPG developers to read and use HEE
• Train economists and statisticians to work
on HEE for CPGs
4. Lack of funding/ insufficient resources • Training and building necessary skills
• Collecting data/evidence to inform economic models
(e.g. clinical outcomes, registries)
• Investment in research and training
5. Lack of trust and inability to share • Poor sharing of available data (e.g. private to public) • Develop agreements between groups to
share data respectfully
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and varied lobby groups who want to have a slice of that
healthcare budget’ [FGP_5].
Context-specific issues affecting use of HEE in CPGs
Context-specific issues are challenges to the processes or
environment under which a CPG is produced, and
therefore not easily changed with adjustments to the
methodological or reporting specifications [20]. Context-
specific issues posed a greater barrier to using HEE in
CPGs than the methods challenges. The lack of a formal
process for consideration of HEE in CPG development
and funding for economics research were considered the
most important context-specific issues affecting use of
HEE in CPGs in South Africa (Fig. 4). Potential solutions
to the context-specific issues (suggested by survey re-
spondents) are summarised in Table 2. Focus group par-
ticipants agreed with the survey findings that HEE is not
consistently included in decision-making processes. At
the heart of this issue was that the demand side (what
policymakers/ funders want or need) is poorly articu-
lated. An academic colleague explained it, ‘I think the
problem is one of the market. Until you have a market
that is specifically saying: “yes we are going to use you,
and this is what we want”, there is no actual consumer
base here that is particularly powerful’ [FGP_5]. It was
also mentioned that the private and public sectors have
different strategies and different capacity to pay high
prices for HEE work, with the public sector ‘always run-
ning along, panting behind because the state can’t afford
it [HEE]’ [FGP_5]. As the country shifts towards the na-
tional health insurance, it was corroborated that ‘buy-in’
from top level government departments including the
Presidency and the Treasury is required to recognise the
value of HEE to drive return on investment. This would
enable informed decisions regarding new technologies as
well as disinvestment in out-of-date technologies.
Current technical ability of CPG developers to enable the
production and use of HEE in CPGs
Most respondents (more than 92%) considered it very or
quite important that producers of HEE should be able to
conduct all the listed types of analyses: Identification,
gathering and synthesis of costing data; analysing and
reporting costing data; budget impact analysis; and eco-
nomic evaluations (including cost-minimisation analysis,
cost-effectiveness analysis, cost-benefit analysis, and
cost-utility analysis). In addition, they suggested that
HEE producers should conduct simple cost comparisons,
impact analyses, programme costing, optimisation ana-
lysis, multi-criteria decision analysis, and interpretation
of external factors that might affect healthcare costs.
The respondents themselves mostly had experience in
commissioning, analysing or using ‘costing analysis’,
followed by ‘budget impact analysis’ and ‘locally pro-
duced economic evaluations’. Respondents had limited
experience in utilising ‘economic evaluations produced
outside of South Africa’. In terms of their own experi-
ence in producing HEE, the respondents had the most
experience in ‘identifying, gathering and synthesising
costing information’, followed by ‘analysing and report-
ing costing data’, ‘budget impact analysis’ and ‘economic
evaluation’. Almost half of the survey respondents (49%,
24/49) were aware of situations in which economic evi-
dence was produced to inform South African CPG
Fig. 4 Ranking context-specific issues that may affect health economic evidence use in CPGs
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development however the majority (67%, 33/49) were
not aware or were unsure if CPG developers in South
Africa formally consider HEE when making recommen-
dations. Focus group participants emphasised the limited
capacity of CPG panel members to read, understand and
use the HEE in their decision-making. Further, there are
differences between the private and public sector regard-
ing what is needed, used and how economic analyses are
funded, which as one academic colleague suggested cur-
rently leads to a: ‘fight between industry funded analyses,
funder funded analyses and the state’ [FGP_5].
Training needs of CPGs developers to produce and use
HEE in CPGs
The three areas in which respondents felt that the CPG
producing community and they themselves would bene-
fit from additional training was in identification, gather-
ing and synthesis of costing information; structured
decision-making process for incorporating HEE into
CPGs; and producing and/or interpreting health eco-
nomic analysis. They provided examples of relevant
courses and considered various training mediums effect-
ive (Fig. 5), with mentorship and on-the-job training
considered the most desirable overall. Focus group par-
ticipants stressed that one first needs clarity regarding
which analyses need doing and for whom before plan-
ning training. They also felt that health economists may
be trained in the field but lack the ‘real world’, ‘prag-
matic’ capacity to undertake these economic analyses in
responsive, accessible, timely and usable ways.
Who needs to build skills, what skills do they need to
build and how do we take it forward?
Focus group participants identified various role players
who need training: research institutions, CPG funders,
CPG panels, various forms of government, funders (in-
cluding treasury), health professionals, clinicians, CPG
end users, professional societies, industry, pharmaceut-
ical industry, civil society. For CPG developers, the cap-
acity to apply the principles of evidence-based medicine,
and not only understand them, is important. They
should have capacity to make decisions in the face of
uncertainty in the research evidence; and they need to
understand the principles and reports of HEE. Formal
training for health economists was not thought to be an
issue, but rather their ability for ‘translating the complex
stuff into common day language’[FGP_2]. Thus, what
was re-iterated was the need for ‘on the job’ training and
being embedded in the positions with clear career
pathing so that those trained can have jobs in the public
Fig. 5 Effectiveness of different approaches to training in economic evaluation
Table 2 Solutions to contextual challenges affecting the use of
economic evidence in CPGs
Solutions for production and use of HEE
• Need for political will and backing
• Training of guideline panels, policymakers and health economists
• Include health economists and others in expert review of analyses
• Health economists to suggest guideline recommendations based on
the health economic evidence and work to increase the transparency
and credibility of analyses
• Public-private partnerships to share evidence and for cross-sectoral
decisions
• Clarify outcomes that matter to decision-makers for use in economic
evaluations
• Need centralised management of health technology assessment (to
commission and fund), a guiding body to coordinate functions
Wilkinson et al. BMC Health Services Research          (2021) 21:738 Page 8 of 12
sector and not only in the private sector. In the con-
tested space of making decisions where ‘political
decision-making trump [s] good economic analysis’,
health economists need skills to ensure that ‘economic
evaluation is packaged and coherent enough and inspir-
ing enough for decision-makers to use’ [FGP_2].
Overall, participants made it clear that training is not
the primary issue and can’t be planned until other more
pressing issues are resolved, such as buy-in, political
backing and clarity regarding what is needed on the ‘de-
mand side’ to inform training. It was suggested that until
you ‘actually define how you are going to use that person
[health economist], the whole debate about how they are
going to act becomes redundant. You really need to find
out what tools you actually need for decision-making in
the country. And then work backwards from that to how
you would change such people and get them to interact
with the system, rather than generate another pie-in-the-
sky guide on a perfect health economist’ [FGP_5].
Discussion
Survey and focus groups participants agreed that HEE
should be used in South Africa to inform CPG decisions,
particularly as the resource constrained context requires
judicious spend on health. Notwithstanding this com-
mon agreement on the importance of economic consid-
erations for decision-making, the methods, approaches
and actual practice of using HEE in CPGs remain chal-
lenging. Globally, methods for using HEE in CPGs have
advanced over the past few decades, with increasing
numbers of ‘guideline for guidelines’ manuals outlining
processes for their CPG group’s needs. Some of these
methods are captured in the Guidelines 2.0 checklist
which systematically considered all guideline manuals
and created a listing of all key steps CPG groups should
consider, including consideration of costs and resources
in decisions [2]. Despite evolving methods for conduct-
ing economic analyses, for our participants, the major
question was not how to do analyses (although that was
part of it) but rather which types of economic analyses
are required to inform specific decisions and how to en-
sure that HEE reporting could be provided in standar-
dised, useful, and accessible ways. Planned reforms
under NHI [15, 23] have the potential to strengthen and
integrate South Africa’s HTA capacity and processes,
which may result in improvement in the methods used
to select, produce and report HEE. This could lead to lo-
cally produced HTAs being a more consistent and valu-
able source of HEE that can be used to inform national
treatment guidelines and benefit packages. Health tech-
nology assessments, costing analyses and economic eval-
uations produced outside of South Africa are other
important reference sources for HEE. Work facilitated
by the GINAHTA working group (represented by
Guidelines International Network and the International
Network of Agencies for Health Technology Assess-
ment) [24] may provide useful insight on how and when
HTAs developed outside of South Africa can be best uti-
lised in the local setting.
Participants, particularly focus group members, sug-
gested that basic costs should generally be considered
during CPG processes, with complex economic analyses
reserved for new or expensive technologies. For the most
part, it was suggested that ‘back of the envelope’ or less
formal considerations of costs could suffice. This aligns
with emerging guidance from multilateral organisations
such as the World Health Organisation (WHO), national
governments and professional societies who have also
grappled with these challenges to clarify which economic
analyses to do when to ensure transparent, equitable
decision-making [25]. The feasibility of producing rele-
vant and useful HEE for CPGs should also be considered
- for example, it will be more difficult to produce HEE
for topics that cover broad clinical areas compared to
topics with a more narrow scope [26]. The American
Thoracic Society (ATS) have developed guidance on
using costing data to inform CPG decisions utilising
pragmatic approaches to ensure complex analyses are
only conducted when needed and likely to be used, and
accessible data on acquisition costs and resources are
presented more often [7]. Both WHO and ATS organi-
sations have adopted rigorous CPG methods with use of
systematic reviews and systematic decision processes,
such as the use of Grading of Recommendations Assess-
ment, Development and Evaluation (GRADE) evidence
to decision tables [27]. As such, what sets these CPG de-
velopers apart from the South African CPG community
is that these groups have established skills in evidence-
based decision-making and have built on that capacity to
further plan when and what to use for informing costs,
resources and costs-effectiveness for CPG recommenda-
tions [7, 25]. Our focus group participants emphasised
insufficient skills in evidence-based medicine in local
CPG groups, adding that the addition of cost consider-
ations, particularly more advanced costing analyses, adds
to the complexity and might hinder rather than help
decision-makers.
Participants identified multiple methodological and
contextual obstacles explaining why HEE is currently
not used to inform CPGs. In addition to the issue of
complexity when adding HEE to decision-making, fur-
ther issues were identified such as inadequate guidance
about which HEE is needed for which decisions (the
‘market’); lack of local data and skills in using global
data; and unclear or lack of standardised methods for
economic analysis. Hence, despite evolution in methods
guides globally outlining how and when to include eco-
nomic analyses, our participants reported that there is
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insufficient methods guidance in South Africa. Further,
in the absence of strong, accepted methods, financial in-
terests are perceived to influence and drive decisions in
CPGs.
Priority setting is a key activity in CPG development
or technology assessment [2, 28]. This is highlighted in
local processes for priority setting for topics for HEE
which was perceived to be driven by financial or non-
financial interests in the absence of methods for doing
this transparently.
Overall, contextual issues emerged as more pressing
than methodological limitations. A particular contextual
issue was South Africa’s two-tiered public and private
healthcare system which has been reported to result in
inequitable access to quality health care and impacts
CPG development processes and implementation [29,
30]. The fault lines between private and public sectors
was thought to impact transparency and consistency
across sectors resulting in inequitable access to health
care services. Further views by focus group participants
indicated that the private sector may have easier access
to costly economic analyses which the public sector
could not access or afford. A proposed solution from the
survey was centralised oversight of guidelines and HEE
set standards to ensure transparency - an approach that
echoes suggestions from other South African CPG re-
search in which national stakeholders identified gaps in
oversight leading to opportunities for interests to drive
decisions and priorities [29]. Models of centralised
health policy decision-making oversight is seen in some
settings as outlined in South African Guidelines Excel-
lence (SAGE) report of all CPG agencies describing the
role and functions [31]. Several examples exist, one that
is particularly relevant to SA is the National Health
Intervention and Technology Assessment Program
(HITAP) in Thailand where methods for considering
HEE are clearly outlined and evolved from the need to
ensure transparency and build public trust [32, 33].
Training and technical capacity in conducting and
using HEE for CPGs was explored. Focus group partici-
pants recommended that all groups involved with
decision-making including researchers, economists, and
policymakers need to build skills in HEE appraisal and
use. It was emphasised in the focus group that for health
economists, training provided through tertiary institu-
tions is not the problem, and that courses likely include
all necessary competencies. In certain academic institu-
tions, the need for capacity strengthening has been
recognised and capacity building in health economics is
proceeding at both the masters and doctoral level. How-
ever, the issue is the gap in translating findings into pol-
icy especially when health economists present highly
technical reports which users such as CPG developers
do not have the capacity to decipher. They suggested
that what is needed are applied skills, communication
skills, and career opportunities (particularly in the public
sector) to work and learn ‘on the job’.
Our participants were clear that HEE are not likely to
inform policy until certain issues are addressed. Firstly,
clarity from South African decision-makers is required
on what types of HEE are needed for what decision, after
which HEE can be produced using rigorous, standar-
dised methods and reported using transparent reporting
guidelines. Next, opportunities for career pathing, on the
job training, and mentorship is needed – on the one
hand to provide health economists with clarity on what
reports are needed and how to translate them for CPG
developers and policymakers. This would be needed in
useful, accessible language. In addition, there is a need
to build capacity amongst CPG developers to appraise
and use HEE - to together work on bridging the gap be-
tween HEE reports and what is needed for a decision.
Limitations and strengths
This study addressed the broad question of the current
practice, training needs and challenges faced by those in-
volved with CPGs and health economics in relation to
production and use of HEE in CPG development. The
survey, followed by a focus group, allowed broad engage-
ment with multiple stakeholders with deeper exploration
among those closely involved with CPG activities.
A potential limitation was whether the sample size was
sufficient in terms numbers of people who are actively
involved with CPG. In order to mitigate this, we used as
broad a sampling approach as possible, including a
snow-balling approach so that the survey could be
shared further. The fact that the sample is skewed to
participants from two provinces - Gauteng and the
Western Cape - likely reflects the major training institu-
tions and inequitable distribution of academics in South
Africa who contribute to CPG development. Further-
more, the focus group size of five was smaller than the
anticipated ten participants. Despite this, the major an-
ticipated stakeholder groups were all represented and
rich inputs were provided that reflected and clarified
views from the survey process.
Strengths of the study include the fact that respon-
dents spent on average 27min completing the survey.
One interpretation is that participants had an interest
and commitment to contributing to this policy
development.
Conclusions
One of the earliest methods guides for developing CPGs
stated: “health interventions are not free, people are not
infinitely rich, and the budgets of [health care] pro-
grammes are limited.” [34–36]. Study respondents rein-
forced the view that affordability and consideration of
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financial resources should always be part of CPG
decision-making.
As South Africa continues in its trajectory to UHC
aiming for an inclusive, equitable health system, study
participants agreed that some form of HEE should al-
ways be considered in CPG decisions, with complex eco-
nomic analyses reserved for new or expensive
technologies. The COVID-19 pandemic has illuminated
the need for healthcare decisions to be informed by evi-
dence of effectiveness, feasibility and costs. However,
without agreed upon methods or processes for using
HEE for decisions, this approach will remain challenging
for those who set the CPGs. Presenting HEE in access-
ible ways for CPG groups is also essential and was
flagged as a concern. Addressing these key issues is an
imperative precursor to successful cost-informed CPG
decision-making in South Africa.
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